Prior research in T2DM and overweight/obese patients has demonstrated that the time‐dependent and progressively diverging response curves between GLP‐1 RAs and placebo on metabolic effects, including weight loss, typically attain statistical significance after a minimum of 6 months of treatment [38]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.